

=>
Uploading C:\Program Files\Stnexp\Queries\10657567b.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR
/ Structure 2 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 12:01:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3592 TO ITERATE

100.0% PROCESSED 3592 ITERATIONS 161 ANSWERS
SEARCH TIME: 00.00.01

L2 161 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
FULL ESTIMATED COST 162.62 162.83

FILE 'CAPLUS' ENTERED AT 12:03:34 ON 31 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 May 2005 VOL 142 ISS 23
FILE LAST UPDATED: 30 May 2005 (20050530/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 4 L2

=> d l3 1-4 ibib abs

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:220301 CAPLUS
DOCUMENT NUMBER: 140:270550
TITLE: A preparation of 1,3-diamino-2-hydroxypropane
 derivatives as beta-secretase enzyme inhibitors

INVENTOR(S): Fobian, Yvette M.; Freskos, John N.; Jagodzinska, Barbara
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
 SOURCE: PCT Int. Appl., 535 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022523	A2	20040318	WO 2003-US28116	20030908
WO 2004022523	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2004214890 A1 20041028 US 2003-657567 20030908 PRIORITY APPLN. INFO.: US 2002-408783P P 20020906 OTHER SOURCE(S): MARPAT 140:270550 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to diamino(hydroxy)propane derivs. of formula I [wherein: R1 = -(CH2)1-2-S(O)0-2-(C1-6 alkyl) or (un)substituted (cyclo)alkyl, alk(en/yn)yl, (hetero)aryl, etc.; R2 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, C2-6 alk(en/yn)yl, etc.; R3 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, etc.; R4 = C1-10 alkyl optionally substituted with 1-3 substituents, -(CH2)0-3-cycloalkyl, -(CR7R8)0-4-(hetero)aryl, etc.; one of R5 and R6 is H and the other is -C(O)(CR9R10)1-6-X-R11, etc.; R7 and R8 are independently selected from H, alkyl, hydroxyalkyl, alk(en/yn)yl, etc.; R9 and R10 are independently selected from H or C1-10 alkyl; R11 = (hetero)aryl, optionally substituted C1-10 alkyl, or C3-8 cycloalkyl, etc.; X = O, S, SO2, etc.]. Compds. I include inhibitors of beta-secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta-peptide in a mammal. Biol. examples include beta-secretase inhibition, assays using synthetic oligopeptide-substrates, inhibition of A beta production in human patients, etc. For instance, compound II (preparation 8) was prepared via amidation of benzoic acid derivative III by diamino(hydroxy)propane derivative IV and subsequent Boc-cleavage (no yield data). Using 19F-NMR an intramol. acyl-migration was observed when compound II was dissolved in DMSO-d6 and pH 4 buffer solution was added.

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:421096 CAPLUS
 DOCUMENT NUMBER: 133:59100
 TITLE: Methods for the synthesis of α -hydroxy- β -amino acid and amide derivatives
 INVENTOR(S): Semple, Joseph E.; Levy, Odile E.

PATENT ASSIGNEE(S): Corvas International, Inc., USA
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035868	A2	20000622	WO 1999-US30267	19991216
WO 2000035868	A3	20010104		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6376649	B1	20020423	US 1998-216134	19981218
CA 2354476	AA	20000622	CA 1999-2354476	19991216
EP 1140854	A2	20011010	EP 1999-967427	19991216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002532466	T2	20021002	JP 2000-588130	19991216
PRIORITY APPLN. INFO.:			US 1998-216134	A 19981218
			WO 1999-US30267	W 19991216

OTHER SOURCE(S): MARPAT 133:59100

AB Methods for the synthesis of α -hydroxy- β -amino acid and amide derivs. and α -ketoamide derivs. and novel derivs. made by these methods are provided. These methods involve reacting an N-terminally blocked (protected) aminoaldehyde with an isonitrile and a carboxylic acid to give an amino- α -acyloxy carboxamide. The acyloxy group may be removed to give the derivative. Alternatively the protecting group is removed and acyl shift occurs to give the derivative. These derivs. are useful in the synthesis of compds. such as peptidyl α -ketoamides and α -hydroxy- β -carboxylic acid and amide derivs. Thus, α -acyloxy- β -protected amino acid derivs. Boc-NHCH[(S)(CH₂)₃NHC(NH₂):NNO₂]CH(O₂CR)CO-Gly-OEt (R = Fmoc-Pro, Alloc-Pro, Ac, Bz, COCH₂CH₂Ph) are among the compds. prepared

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:17574 CAPLUS

DOCUMENT NUMBER: 116:17574

TITLE: Purification to apparent homogeneity by immunoaffinity chromatography and partial characterization of the GM3 ganglioside-forming enzyme, CMP-sialic acid:lactosylceramide α 2,3-sialyltransferase (SAT-1), from rat liver Golgi [Erratum to document cited in C115(1):3719v]

AUTHOR(S): Melkerson-Watson, Lyla J.; Sweeley, Charles C.

CORPORATE SOURCE: Dep. Biochem., Michigan State Univ., East Lansing, MI, 48824, USA

SOURCE: Journal of Biological Chemistry (1991), 266(29), 19865
 CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An error in the text has been corrected. The error was not reflected in the abstract or the index entries.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:403719 CAPLUS
 DOCUMENT NUMBER: 115:3719
 TITLE: Purification to apparent homogeneity by immunoaffinity chromatography and partial characterization of the GM3 ganglioside-forming enzyme, CMP-sialic acid:lactosylceramide α 2,3-sialyltransferase (SAT-1), from rat liver Golgi
 AUTHOR(S): Melkerson-Watson, Lyla J.; Sweeley, Charles C.
 CORPORATE SOURCE: Dep. Biochem., Michigan State Univ., East Lansing, MI, 48824, USA
 SOURCE: Journal of Biological Chemistry (1991), 266(7), 4448-57
 CODEN: JBCHA3; ISSN: 0021-9258
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Lactosylceramide α 2,3-sialyltransferase (SAT-1) was purified .apprx.40,000-fold to apparent homogeneity from rat liver Golgi apparatus. SAT-1 was solubilized from Golgi vesicles in 5% lauryldimethylamine oxide and partially purified by affinity chromatog. twice on CMP-hexanolamine and once on lactosylceramide aldehyde-Sepharose 4B. Final purification was achieved by immunoaffinity chromatog. on M12GC7-Gel 10. The M12GC7 monoclonal antibody specifically inhibited and immunopptd. SAT-1 activity. Identification of the protein, with an apparent mol. weight by SDS-PAGE of .apprx.60,000 daltons, was confirmed by Western blot and immunodetection with M12GC7. SAT-1 specifically catalyzed the transfer of N-acetylneuraminic acid (NeuAc, sialic acid) to lactosylceramide (Gal β 1-4Glc β 1-O-ceramide), forming GM3 ganglioside. Studies on substrate specificity indicated that the preferred acceptors have the general structure, saccharide β 1-O-ceramide, a disaccharide being preferred to a monosaccharide. SAT-1 was found to be a glycoprotein. The carbohydrate moieties were detected with specific lectins. Deglycosylation of SAT-1 with N-glycanase resulted in an increase in a 43,000-dalton band. The 2-dimensional electrophoretogram of SAT-1 indicated a pI range of 5.7-6.2 for the 60,000-dalton protein.

=>